Top

CardioVascular and Interventional Radiology

Published in:

01-05-2005 | Review

Treatment of Neuroendocrine Cancer Metastatic to the Liver: The Role of Ablative Techniques

Authors: T.D. Atwell, J.W. Charboneau, F.G. Que, J. Rubin, B.D. Lewis, D.M. Nagorney, M.R. Callstrom, M.A. Farrell, H.C. Pitot, T.J. Hobday

Published in: CardioVascular and Interventional Radiology | Issue 4/2005

Abstract

Carcinoid tumors and islet cell neoplasms are neuroendocrine neoplasms with indolent patterns of growth and association with bizarre hormone syndromes. These tumors behave in a relatively protracted and predictable manner, which allows for multiple therapeutic options. Even in the presence of hepatic metastases, the standard of treatment for neuroendocrine malignancy is surgery, either with curative intent or for tumor cytoreduction, i.e., resection of 90% or more of the tumor volume. Image-guided ablation, as either an adjunct to surgery or a primary treatment modality, can be used to treat neuroendocrine cancer metastatic to the liver. Image-guided ablative techniques, including radiofrequency ablation, alcohol injection, and cryoablation, can be used in selected patients to debulk hepatic tumors and improve patient symptoms. Although long-term follow-up data are not available, the surgical literature indicates that significant ablative debulking may improve patient survival. In this review, we discuss metastatic neuroendocrine disease and its treatment options, especially image-guided ablative techniques.

Moertel CG (1987) Karnofsky memorial lecture: An odyssey in the land of small tumors. J Clin Oncol 5:1502–1522PubMed

Modlin IM, Sandor A (1997) An analysis of 8305 cases of carcinoid tumors. Cancer 79:813–829CrossRefPubMed

Ihse I, Persson B, Tibblin S (1995) Neuroendocrine metastases of the liver. World J Surg 19:76–82CrossRefPubMed

Proye C (2001) Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: Place for chemoembolization. World J Surg 25:685–688CrossRefPubMed

Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229:815–821CrossRefPubMedPubMedCentral

Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH (1961) Life history of the carcinoid tumor of the small intestine. Cancer 14:901–912CrossRefPubMed

Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G (1995) Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425:547–560CrossRefPubMed

Carty SE, Jensen RT, Norton JA (1992) Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 112:1024–1031PubMed

Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA (1998) Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 187:88–92CrossRefPubMed

10.

Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH (2000) Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 190:432–445CrossRefPubMed

11.

Grazi GL, Cescon M, Pierangeli F, Ercolani G, Gardini A, Cavallari A, Mazziotti A (2000) Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 47:481–486PubMed

12.

Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169:36–42CrossRefPubMed

13.

Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37CrossRefPubMed

14.

Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y (1996) Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 20:908–914CrossRefPubMed

15.

McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108:1091–1096PubMed

16.

Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma: An analysis of 103 patients. Transplantation 66:1307–1312CrossRefPubMed

17.

Knechtle SJ, Kalayoglu M, D’Alessandro AM, Rikkers LF (1997) Proceed with caution: Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 225:345–346CrossRefPubMedPubMedCentral

18.

Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH (1999) Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10:397–403CrossRefPubMed

19.

Clouse ME, Perry L, Stuart K, Stokes KR (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55 [Suppl 3]:92–97PubMed

20.

Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83:2293–2301CrossRefPubMed

21.

Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, Rubin J, Kunselman S (1994) The management of patients with advanced carcinoma tumors and islet cell carcinomas. Ann Intern Med 120:302–309CrossRefPubMed

22.

Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K (1994) [¹¹¹In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 131:577–581CrossRefPubMed

23.

Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50:5969–5977PubMed

24.

Oberg K (2001) Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12 [Suppl 2]:S111–S114CrossRefPubMed

25.

Oberg K (1999) Neuroendocrine gastrointestinal tumors: A condensed overview of diagnosis and treatment. Ann Oncol 10 [Suppl 2]:S3–S8CrossRefPubMed

26.

Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21:36–38CrossRefPubMed

27.

Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523CrossRefPubMed

28.

Eriksson B, Oberg K (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32:203–208CrossRefPubMed

29.

Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E (2002) Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13:614–621CrossRefPubMed

30.

Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26:985–990CrossRefPubMed

31.

Oberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L, Jonsdottir B, Magnusson A, Wilander E (1986) Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treat Rep 70:1297–1304PubMed

32.

Moertel CG, Rubin J, Kvols LK (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7:865–868PubMed

33.

Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E, Vatn MH, Bergan A (1995) Interferon-alpha 2b, with or without prior hepatic artery embolization: Clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 30:789–796CrossRefPubMed

34.

Oberg K (2000) State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 44:3–12PubMed

35.

Biesma B, Willemse PH, Mulder NH, Verschueren RC, Kema IP, de Bruijn HW, Postmus PE, Sleijfer DT, de Vries EG (1992) Recombinant interferon alpha-2b in patients with metastatic apudomas: Effect on tumours and tumour markers. Br J Cancer 66:850–855CrossRefPubMedPubMedCentral

36.

Bowles BJ, Machi J, Limm WM, Severino R, Oishi AJ, Furumoto NL, Wong LL, Oishi RH (2001) Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg 136:864–869CrossRefPubMed

37.

Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 230:1–8CrossRefPubMedPubMedCentral

38.

Dodd GD III, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, Gillams AR, Karahan OI, Rhim H (2000) Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics 20:9–27CrossRefPubMed

39.

Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer: Initial experience in 24 patients. Radiology 220:145–149CrossRefPubMed

40.

Parikh AA, Curley SA, Fornage BD, Ellis LM (2002) Radiofrequency ablation of hepatic metastases. Semin Oncol 29:168–182CrossRefPubMed

41.

Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ (2000) Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications. Ann Surg Oncol 7:593–600CrossRefPubMed

42.

Solbiati L, Livragh T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: Long-term results in 117 patients. Radiology 221:159–166CrossRefPubMed

43.

de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A (2000) Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 175:1619–1625CrossRefPubMed

44.

Solbiati L, Ierace T, Tonolini M, Osti V, Cova L (2001) Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 13:149–158CrossRefPubMed

45.

Cioni D, Lencioni R, Bartolozzi C (2001) Percutaneous ablation of liver malignancies: Imaging evaluation of treatment response. Eur J Ultrasound 13:73–93CrossRefPubMed

46.

Henn AR, Levine EA, McNulty W, Zagoria RJ (2003) Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol 181:1005–1010CrossRefPubMed

47.

Wessels FJ, Schell SR (2001) Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 95:8–12CrossRefPubMed

48.

Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A (2002) Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26:1052–1056CrossRefPubMed

49.

Giovannini M, Seitz JF (1994) Ultrasound-guided percutaneous alcohol injection of small liver metastases: Results in 40 patients. Cancer 73:294–297CrossRefPubMed

50.

Livraghi T, Vettori C, Lazzaroni S (1991) Liver metastases: Results of percutaneous ethanol injection in 14 patients. Radiology 179:709–712CrossRefPubMed

51.

Giovannini M (2002) Percutaneous alcohol ablation for liver metastasis. Semin Oncol 29:192–195CrossRefPubMed

52.

Seifert JK, Cozzi PJ, Morris DL (1998) Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14:175–183CrossRefPubMed

53.

Cozzi PJ, Englund R, Morris DL (1995) Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 76:501–509CrossRefPubMed

54.

Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP (1997) Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122:1040–1047CrossRefPubMed

Title: Treatment of Neuroendocrine Cancer Metastatic to the Liver: The Role of Ablative Techniques
Authors: T.D. Atwell
J.W. Charboneau
F.G. Que
J. Rubin
B.D. Lewis
D.M. Nagorney
M.R. Callstrom
M.A. Farrell
H.C. Pitot
T.J. Hobday
Publication date: 01-05-2005
Publisher: Springer US
Published in: CardioVascular and Interventional Radiology / Issue 4/2005
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-004-4082-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of Neuroendocrine Cancer Metastatic to the Liver: The Role of Ablative Techniques

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2005

Inadvertent Embolization of a Persistent Sciatic Artery in Pelvis Trauma

Percutaneous Transcholecystic Biliary Interventions Using Gallbladder Anchors: Feasibility Study in the Swine

Tumor Seeding Following Lung Radiofrequency Ablation: A Case Report

Percutaneous Thrombin Injection to Complete SMA Pseudoaneurysm Exclusion After Failing of Endograft Placement

Endovascular Treatment of Proximal Bilateral Iliac Limb Dislocation and Kinking following Endovascular Abdominal Aortic Aneurysm Repair

Salvage of Immature Arteriovenous Fistulas with Percutaneous Transluminal Angioplasty